BioCurex Reports Results On Blood Test for Ovarian Cancer With A Market Potential Of $200 Million -- Test Outperforms Current Reference Assay.Business Editors/Health/Medical Writers RANCHO ran·cho n. pl. ran·chos Southwestern U.S. 1. A hut or group of huts for housing ranch workers. 2. A ranch. SANTA MARGARITA Santa Margarita ("Saint Margaret") may refer to:
BioCurex Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:BOCX) announced an estimate of 25% penetration of this $200 million market within the next 3 years via licensing agreements with major diagnostic companies on a worldwide basis. The results further support the use of Serum-RECAF(TM) as a universal cancer marker with a potential total market size for all cancers of $2 billion per year. The results for ovarian cancer ovarian cancer Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast using Serum-RECAF(TM) show a sensitivity of 90% with 95% specificity(a). The current marker of choice marker of choice A lab parameter used to evaluate disease response to therapy and monitor for recurrence; MOCs include RNA for progression of HIV infection and CEA for colorectal cancer for ovarian cancer is CA-125 and it has a sensitivity of only 77% (Dis. Markers 1998, 14(3), 155-60) compared with the 90% found with Serum-RECAF(TM). The study included approximately 140 normal blood samples and 140 ovarian cancer samples. The accumulated results so far obtained with Serum-RECAF(TM) are summarized in the table below: Cancer Type Sensitivity Cases Ovary 90% 140 Breast 100% 22 Stomach 84% 31 Miscellaneous 100% 39 TOTAL 91% 232 BioCurex President Ricardo Moro stated: "Statistics are cold numbers. What these results really mean is that using Serum-RECAF(TM) we could detect, every year, an additional 3,500 women in the USA and 70,000 worldwide that would be diagnosed as negative with the standard test for ovarian cancer. Moreover, the fact that the test is more sensitive than CA-125 suggests that it could detect ovarian cancers at an earlier stage. "There is additional work that needs to be done and our results need to be validated by independent laboratories, an initiative we are pursuing vigorously. However, we have now accumulated over 200 samples from different types of cancer and the overall rate of detection is an impressive 90% with 95% specificity." Dr. Moro added: "The ovarian cancer results are consistent with those obtained on other types of cancer and further support the concept that Serum-RECAF(TM) can be used as a universal cancer test, suitable for massive screening. This has obvious implications from a medical point of view, as well as from a commercial point of view." About BioCurex BioCurex is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor tumor: see neoplasm. imaging and therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. The Histo-RECAF(TM) kits provide proof of concept for the RECAF technology. Detailed information about BioCurex may be obtained from its Web site at www.biocurex.biz biz n. Informal Business. biz Noun Informal business Noun 1. . Note: The company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this news release, which are not historical facts, are "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning given to that term in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The company intends that such forward-looking statements be subject to the safe harbors Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the company's actual results could differ materially from expected results. (a) Sensitivity is the number of true cancers picked by the test. Specificity is the percentage of normal samples that are negative with the test. Since 100% specificity is usually unattainable in biological systems, sensitivity is measured at an accepted specificity value of 95%. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion